A generic method to construct new customized-shaped haotic systems using the relative motion concept

Constructing chaotic systems tailored for each particular real-world application has been a long-term research desideratum. We report a solution for this problem based on the concept of relative motion. We investigate the periodic motion on a closed contour of a coordinate frame in which a chaotic system evolves. By combining these two motions (periodic on a close contour and chaotic) new customized shape trajectories are acquired. We demonstrate that these trajectories obtained in the stationary frame are also chaotic and, moreover, conserve the Lyapunov exponents of the initial chaotic system. Based on this finding we developed an innovative method to construct new chaotic systems with customized shapes, thus fulfilling the requirements of any particular application of chaos

Path Planning Algorithm based on Arnold Cat Map for Surveillance UAVs

During their task accomplishment, autonomous unmanned aerial vehicles are facing more and more threats coming from both ground and air. In such adversarial environments, with no a priori information about the threats, a flying robot in charge with surveilling a specified 3D sector must perform its tasks by evolving on misleading and unpredictable trajectories to cope with enemy entities. In our view, the chaotic dynamics can be the cornerstone in designing unpredictable paths for such missions, even though this solution was not exploited until now by researchers in the 3D context. This paper addresses the flight path-planning issue for surveilling a given volume in adversarial conditions by proposing a proficient approach that uses the chaotic behaviour exhibited by the 3D Arnold’s cat map. By knowing the exact location of the volume under surveillance before take-off, the flying robot will generate the successive chaotic waypoints only with onboard resources, in an efficient manner. The method is validated by simulation in a realistic scenario using a detailed Simulink model for the X-4 Flyer quadcopter

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

Background: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice (IP) single-arm, open-label extension substudy. Objective: Assess potential for standard-of-care background medication reductions while maintaining asthma control with benralizumab. Methods: Following ANDHI DB completion, eligible adults were enrolled in ANDHI IP. After an 8-week run-in with benralizumab, there were 5 visits to potentially reduce background asthma medications for patients achieving and maintaining protocol-defined asthma control with benralizumab. Main outcome measures for non-oral corticosteroid (OCS)-dependent patients were the proportions with at least 1 background medication reduction (ie, lower inhaled corticosteroid dose, background medication discontinuation) and the number of adapted Global Initiative for Asthma (GINA) step reductions at end of treatment (EOT). Main outcomes for OCS-dependent patients were reductions in daily OCS dosage and proportion achieving OCS dosage of 5 mg or lower at EOT. Results: For non-OCS-dependent patients, 53.3% (n = 208 of 390) achieved at least 1 background medication reduction, increasing to 72.6% (n = 130 of 179) for patients who maintained protocol-defined asthma control at EOT. A total of 41.9% (n = 163 of 389) achieved at least 1 adapted GINA step reduction, increasing to 61.8% (n = 110 of 178) for patients with protocol-defined EOT asthma control. At ANDHI IP baseline, OCS dosages were 5 mg or lower for 40.4% (n = 40 of 99) of OCS-dependent patients. Of OCS-dependent patients, 50.5% (n = 50 of 99) eliminated OCS and 74.7% (n = 74 of 99) achieved dosages of 5 mg or lower at EOT. Conclusions: These findings demonstrate benralizumab's ability to improve asthma control, thereby allowing background medication reduction